tariquidar has been researched along with vanadates in 2 studies
| Studies (tariquidar) | Trials (tariquidar) | Recent Studies (post-2010) (tariquidar) | Studies (vanadates) | Trials (vanadates) | Recent Studies (post-2010) (vanadates) |
|---|---|---|---|---|---|
| 210 | 16 | 138 | 5,200 | 7 | 785 |
| Protein | Taxonomy | tariquidar (IC50) | vanadates (IC50) |
|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 0.0254 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callaghan, R; Heyward, C; Modok, S | 1 |
| Garabadzhiu, A; Grigoreva, T; Novikova, D; Romanova, A; Sagaidak, A; Tribulovich, V | 1 |
2 other study(ies) available for tariquidar and vanadates
| Article | Year |
|---|---|
P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; CHO Cells; Cholesterol; Cricetinae; Kinetics; Liposomes; Membrane Microdomains; Models, Biological; Nicardipine; Phosphatidylcholines; Quinolines; Sphingolipids; Vanadates | 2004 |
Establishment of drug-resistant cell lines under the treatment with chemicals acting through different mechanisms.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Drug Resistance, Neoplasm; Enzyme Inhibitors; HCT116 Cells; Humans; Imidazoles; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-mdm2; Quinolines; Vanadates | 2021 |